Innovus Pharmaceuticals, Inc. (INNV: OTCQB) | Innovus Pharma Launches AllerVarx, a Clinically Proven Supplement for the Relief of Allergy Symptoms, in the United States

Innovus Pharma Launches AllerVarx, a Clinically Proven Supplement for the Relief of Allergy Symptoms, in the United States

May 24, 2017

OTC Disclosure News Service

Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company”) (OTCQB
Venture Market: INNV), an emerging commercial-stage pharmaceutical
company that delivers safe, innovative and effective over-the-counter
medicine and consumer care products to improve men’s and women’s health
and respiratory diseases, today announced the launch of AllerVarx™ in
the U.S. AllerVarx™ is a clinically proven supplement, scientifically
formulated for the relief of allergy symptoms.

“Launching AllerVarx™ strengthens our respiratory franchise and provides
us with the potential to cross sell or potentially be sold in a kit
format with our product FlutiCare™, for which we announced a commercial
partnership recently,” said Dr. Bassam Damaj, President and Chief
Executive Officer of Innovus Pharma. “We currently believe the product
could generate at least an additional $1.0 million per year in revenues
from the launch date. This product, combined eventually with FlutiCare™,
should provide us with an immense advantage over our competitors. In
addition, we are looking to further expand our respiratory franchise
through the in-license of other products in this field.”

AllerVarx™, sold in Europe under the brand name Lertal®, is a product
the Company exclusively in-licensed for the U.S. and Canada from NTC
s.r.l., an Italian company, and is a patented formulation produced in
bilayer tablets with a technology that allows a controlled release of
the ingredients. The fast-release layer allows the rapid antihistaminic
activity of Perilla. The sustained-release layer enhances Quercetin and
Vitamin D3 bioavailability, thanks to its lipidic matrix, and
exerts anti-allergic activity spread over time.

AllerVarx™ was studied in a published clinical trial assessing the
reduction of both nasal and ocular symptoms in allergic patients, and
daily consumption of anti-allergic drugs, over a period of 30 days. AllerVarx™
showed a reduction of approximately 70% in total symptom scores and a
reduction of approximately 73% in the use of anti-allergic drugs. There
were no side effects noted during the administration of AllerVarx™ and
all the patients enrolled finished the study with good compliance.

The World Health Organization (“WHO”) classifies allergies as the fourth
most important chronic disease in the world. Allergic Rhinitis (“AR”) is
the most common form of non-infectious rhinitis, affecting between 10%
and 30% of all adults in the United States, and as many as 40% of U.S.
children. Epidemiologic studies show that the prevalence of AR is
expected to still be important in the next decades. The World Allergy
Organization (“WAO”) has estimated that 400 million people in the world
suffer from AR, which remains to a large extent underdiagnosed
and undertreated.

About AllerVarx™

AllerVarx™ is a patented formulation produced in bilayer tablets with a
technology that allows a controlled release of the ingredients. The
fast-release layer allows the rapid antihistaminic activity of Perilla.
The sustained-release layer enhances Quercetin and Vitamin D3
bioavailability, thanks to its lipidic matrix, and exerts anti-allergic
activity spread over time. For more information on the product please
visit www.allervarx.com.

About Innovus Pharmaceuticals, Inc.

Headquartered in San Diego, Innovus Pharma is an emerging
over-the-counter (“OTC”) consumer goods and specialty pharmaceutical
company engaged in the commercialization, licensing and development of
safe and effective non-prescription medicine and consumer care products
to improve men’s and women’s health and vitality and respiratory
diseases. Innovus Pharma delivers innovative and uniquely presented and
packaged health solutions through its (a) OTC medicines and consumer and
health products, which we market directly; (b) commercial partners to
primary care physicians, urologists, gynecologists and therapists; and
(c) directly to consumers through our on-line channels, retailers and
wholesalers. The Company is dedicated to being a leader in developing
and marketing new OTC and branded Abbreviated New Drug Application
(“ANDA”) products. The Company is actively pursuing opportunities where
existing prescription drugs have recently, or are expected to, change
from prescription (or Rx) to OTC.

For more information, go to www.innovuspharma.com,
www.zestra.com,
www.ejectdelay.com,
www.myvesele.com,
www.urivarx.com,
www.sensumplus.com,
www.myandroferti.com,
www.beyondhumantestosterone.com,
www.getbeyondhuman.com,
www.trybeyondhuman.com,
www.recalmax.com,
www.prostagorx.com,
www.fluticare.com
and www.allervarx.com.

Innovus Pharma’s Forward-Looking Safe Harbor:

Statements under the Private Securities Litigation Reform Act, as
amended: with the exception of the historical information contained in
this release, the matters described herein contain forward-looking
statements that involve risks and uncertainties that may individually or
mutually impact the matters herein described for a variety of reasons
that are outside the control of the Company, including, but not limited
to, projected revenues from the AllerVarx™ product in the U.S.,
projected online subscribers, estimated market for its products, and
statements about achieving its other development, growth,
commercialization, financial and staffing objectives. Readers are
cautioned not to place undue reliance on these forward-looking
statements as actual results could differ materially from the
forward-looking statements contained herein. Readers are urged to read
the risk factors set forth in the Company’s most recent filing on Form
S-1, annual report on Form 10-K, subsequent quarterly reports filed on
Form 10-Q and other filings made with the SEC. Copies of these reports
are available from the SEC’s website or without charge from the Company.

Copyright © 2017 Businesswire. All Rights Reserved

The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.

Article source: http://www.otcmarkets.com/stock/INNV/news?id=159922

Leave a Reply

WP2Social Auto Publish Powered By : XYZScripts.com
Bunk Beds